Protein / target

DNA gyrase subunit A

gyrAP0AES4Escherichia coli (strain K12)Swiss-Prot
30
Clinical trials
2
Drugs targeting

Protein at a glance

Biological role

ATP-dependent activity, acting on DNA

Derived from structured UniProt, Open Targets and literature data on this page.

Protein profile

UniProt 2026_02

Canonical identity and biological annotation from UniProt.

Function

A type II topoisomerase that negatively supercoils closed circular double-stranded (ds) DNA in an ATP-dependent manner to maintain chromosomes in an underwound state (PubMed:12051842, PubMed:18642932, PubMed:186775, PubMed:19060136, PubMed:19965760, PubMed:20356737, PubMed:22457353, PubMed:23294697, PubMed:3031051, PubMed:7811004, PubMed:9148951). This makes better substrates for topoisomerase IV (ParC and ParE) which is the main enzyme that unlinks newly replicated chromosomes in E.coli (PubMed:9334322). Gyrase catalyzes the interconversion of other topological isomers of dsDNA rings, including catenanes (PubMed:22457352). Relaxes negatively supercoiled DNA in an ATP-independent manner (PubMed:337300). E.coli gyrase has higher supercoiling activity than many other bacterial gyrases; at comparable concentrations E.coli gyrase introduces more supercoils faster than M.tuberculosis gyrase, while M.tuberculosis gyrase has higher decatenation than supercoiling activity compared to E.coli (PubMed:22457352). E.coli makes 15% more negative supercoils in pBR322 plasmid DNA than S.typhimurium; the S.typhimurium GyrB subunit is toxic in E.coli, while the E.coli copy can be expressed in S.typhimurium even though the 2 subunits have 777/804 residues identical (PubMed:17400739). The enzymatic differences between E.coli gyrase and topoisomerase IV are largely due to the GyrA C-terminal domain (approximately residues 524-841) and specifically the GyrA-box (PubMed:16332690, PubMed:8962066)

Subcellular location

Cytoplasm
Domains and Gene Ontology detail (18)

Domains & features

Topo IIA-type catalytic

Gene Ontology

  • Cchromosome
  • Ccytoplasm
  • Ccytosol
  • CDNA topoisomerase type II (double strand cut, ATP-hydrolyzing) complex
  • Cmembrane
  • FATP binding
  • FATP-dependent activity, acting on DNA
  • FDNA binding
  • FDNA negative supercoiling activity
  • FDNA topoisomerase type II (double strand cut, ATP-hydrolyzing) activity
  • Fidentical protein binding
  • PDNA topological change

875 aa · 97 kDa

Biological roles

Reactome v97

What this protein does, drawn together from its UniProt function, Gene Ontology terms and Reactome pathways.

Transcriptional regulationGO
View supporting evidence

Transcriptional regulation

  • ·DNA-templated transcription
View underlying pathways (2)

Concepts derived from UniProt GO Reactome — each badge above shows which sources supported that role.

Drugs targeting this protein

2

Whether each drug engages this protein directly or through a complex, and how many other targets are recorded for it. Direct binders with few recorded targets are listed first.

Ofloxacin
Inhibitor

Bacterial DNA gyrase inhibitor

Acts on a complex — shared with gyrB · 1 of 2 recorded protein targets — narrow recorded profile

Ciprofloxacin
Inhibitor

Bacterial DNA gyrase inhibitor

Acts on a complex — shared with gyrB · 1 of 4 recorded protein targets

ChEMBL mechanism, action type and target identity. Open Targets clinical status and indications.

Clinical trials

30

Trials of drugs that target this protein — reached indirectly through those drugs, so a trial listed here studies the drug, not the protein.

Show remaining trials (24)

COMPLETED · via Ciprofloxacin · NCT00791505

COMPLETED · via Ciprofloxacin · NCT02340182

ClinicalTrials.gov via the drug-target graph.

What's happening now

60

Recent activity around this target, drawn from one canonical event stream. Every item is reached through 2 drugs that target this protein, so each event is news about that drug rather than about the protein directly.

  1. Industry development2026-07-27
    Catalytic degradation of ciprofloxacin via peroxymonosulfate activation using a UiO66 and amino functionalized silica coated magnetite composite

    Nature — Environmental Sciences · news · via Ciprofloxacin

  2. Label change2026-07-22

    Label change: CIPROFLOXACIN (ANDA076558)

    fda · regulatory · fda · via Ciprofloxacin

  3. Label change2026-07-22

    Label change: CIPROFLOXACIN (ANDA076794)

    fda · regulatory · fda · via Ciprofloxacin

  4. Industry development2026-07-02
    Adsorption of ciprofloxacin onto engineered biochar derived from floating aquatic weed biomass with isotherm kinetic and interaction mechanism analysis

    Nature — Environmental Sciences · news · via Ciprofloxacin

  5. New publication2024-01-07
    Compatible co-administration of BioThrax® vaccine and ciprofloxacin-Results of a randomized open-label drug-vaccine interaction trial.

    Vaccine: X · 2024 · 1 citation · Europe PMC · via Ciprofloxacin

  6. New publication2023-09-12
    Global diversity and antimicrobial resistance of typhoid fever pathogens: Insights from a meta-analysis of 13,000 <i>Salmonella</i> Typhi genomes.

    eLife · 2023 · 93 citations · Europe PMC · via Ciprofloxacin

  7. Label change2023-08-31

    Label change: CIPROFLOXACIN (ANDA076558)

    fda · regulatory · fda · via Ciprofloxacin

  8. Label change2023-08-31

    Label change: CIPROFLOXACIN (ANDA076558)

    fda · regulatory · fda · via Ciprofloxacin

  9. Label change2023-08-31

    Label change: CIPROFLOXACIN (ANDA076558)

    fda · regulatory · fda · via Ciprofloxacin

  10. Label change2023-08-31

    Label change: CIPROFLOXACIN (ANDA076558)

    fda · regulatory · fda · via Ciprofloxacin

  11. Label change2023-08-31

    Label change: CIPROFLOXACIN (ANDA076558)

    fda · regulatory · fda · via Ciprofloxacin

  12. Label change2023-08-31

    Label change: CIPROFLOXACIN (ANDA076558)

    fda · regulatory · fda · via Ciprofloxacin

Objective event titles are shown unmodified; the event kind and significance line are derived from structured fields. Forefront AttentionEvent stream aggregating Europe PMC Regulatory filings ClinicalTrials.gov.